Literature DB >> 23695040

Onabotulinum toxin A for treatment of chronic migraine with medication overuse.

L Grazzi1.   

Abstract

Chronic migraine is a common and debilitating headache syndrome. Botulinum neurotoxin (BoNT), a potent toxin produced by the anaerobic bacterium Clostridium botulinum, used largely for treatment of disorders associated with increased muscle tone and hyperidrosis, has been recently used for patients suffering from chronic migraine. In this study, two groups of patients were treated with different dosages of BoNT A to verify the efficacy for chronic migraine. The results confirmed the efficacy of BoNT A when used at the dosage of 150 U. In the second group of patients treated with 100 U, results were not significant. Although these results are preliminary, they led to intense efforts to evaluate the analgesic properties of BoNT A and to assess their clinical applicability.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23695040     DOI: 10.1007/s10072-013-1381-1

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  11 in total

1.  The International Classification of Headache Disorders: 2nd edition.

Authors: 
Journal:  Cephalalgia       Date:  2004       Impact factor: 6.292

Review 2.  Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A.

Authors:  K R Aoki
Journal:  Neurotoxicology       Date:  2005-07-05       Impact factor: 4.294

3.  New appendix criteria open for a broader concept of chronic migraine.

Authors:  J Olesen; M-G Bousser; H-C Diener; D Dodick; M First; P J Goadsby; H Göbel; M J A Lainez; J W Lance; R B Lipton; G Nappi; F Sakai; J Schoenen; S D Silberstein; T J Steiner
Journal:  Cephalalgia       Date:  2006-06       Impact factor: 6.292

4.  Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial.

Authors:  Ninan T Mathew; Benjamin M Frishberg; Marek Gawel; Rozalina Dimitrova; John Gibson; Catherine Turkel
Journal:  Headache       Date:  2005-04       Impact factor: 5.887

5.  Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program.

Authors:  Andrew Blumenfeld; Stephen D Silberstein; David W Dodick; Sheena K Aurora; Catherine C Turkel; William J Binder
Journal:  Headache       Date:  2010-10       Impact factor: 5.887

Review 6.  Evidence for antinociceptive activity of botulinum toxin type A in pain management.

Authors:  K Roger Aoki
Journal:  Headache       Date:  2003 Jul-Aug       Impact factor: 5.887

Review 7.  Medication-overuse headache: a worldwide problem.

Authors:  Hans-Christoph Diener; Volker Limmroth
Journal:  Lancet Neurol       Date:  2004-08       Impact factor: 44.182

8.  Treatment of chronic migraine with medication overuse: is drug withdrawal crucial?

Authors:  Licia Grazzi; Frank Andrasik; Susanna Usai; Gennaro Bussone
Journal:  Neurol Sci       Date:  2009-05       Impact factor: 3.307

9.  Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin.

Authors:  Parisa Gazerani; Natalia Spicina Pedersen; Camilla Staahl; Asbjørn Mohr Drewes; Lars Arendt-Nielsen
Journal:  Pain       Date:  2008-11-11       Impact factor: 6.961

10.  Botulinum toxin type-A in the prophylactic treatment of medication-overuse headache: a multicenter, double-blind, randomized, placebo-controlled, parallel group study.

Authors:  Giorgio Sandrini; Armando Perrotta; Cristina Tassorelli; Paola Torelli; Filippo Brighina; Grazia Sances; Giuseppe Nappi
Journal:  J Headache Pain       Date:  2011-04-16       Impact factor: 7.277

View more
  4 in total

Review 1.  Therapeutic use of botulinum toxin in migraine: mechanisms of action.

Authors:  Roshni Ramachandran; Tony L Yaksh
Journal:  Br J Pharmacol       Date:  2014-09       Impact factor: 8.739

Review 2.  Treatment of Chronic Migraine with OnabotulinumtoxinA: Mode of Action, Efficacy and Safety.

Authors:  Délia Szok; Anett Csáti; László Vécsei; János Tajti
Journal:  Toxins (Basel)       Date:  2015-07-17       Impact factor: 4.546

3.  Topographic Relationship between the Supratrochlear Nerve and Corrugator Supercilii Muscle--Can This Anatomical Knowledge Improve the Response to Botulinum Toxin Injections in Chronic Migraine?

Authors:  Hyung-Jin Lee; Kwang-Seok Choi; Sung-Yoon Won; Prawit Apinuntrum; Kyung-Seok Hu; Seong-Taek Kim; Tanvaa Tansatit; Hee-Jin Kim
Journal:  Toxins (Basel)       Date:  2015-07-17       Impact factor: 4.546

4.  Onabotulinumtoxin-A treatment in Greek patients with chronic migraine.

Authors:  Michail Vikelis; Andreas A Argyriou; Emmanouil V Dermitzakis; Konstantinos C Spingos; Dimos D Mitsikostas
Journal:  J Headache Pain       Date:  2016-09-17       Impact factor: 7.277

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.